AMP Biosimilars AG is strengthening its Management and Supervisory Boards. Gunnar Janssen has stepped down as Deputy Chairman of the Supervisory Board with immediate effect and will continue as Chief Financial Officer, responsible for Finance, Controlling, and Investor Relations. The expansion of the Management Board comes in the run-up of pending contracts with international partners.

Mr. Janssen, who began his career with Deutsche Bank and has over 25 years of experience in the financial sector in Frankfurt, Zurich, and London, will be an asset to amp biosimilars AG. Mr. Janssen has served in various leadership positions, including for Deutsche Bank Capital Markets, Credit Suisse First Boston, Barclays, Commerzbank Securities, Lehman Brothers, and Donaldson, Lufkin & Jenrette. Throughout his career, Mr. Janssen has been responsible for numerous capital market transactions and has built up a comprehensive network in corporate finance and capital markets.

Most recently, he served as Chairman of the Board and Managing Director of German Private Equity GmbH. Dr. Thomas Zimmer will assume Mr. Janssen's role on the Supervisory Board and direct the body as its new Chairman. Dr. Zimmer has over 34 years of experience in the pharmaceutical industry, including in various senior leadership positions at Boehringer Ingelheim, where he also gained experience abroad in locations such as Brazil, Spain, and the USA.

He implemented the European manufacturing alliance, where he was responsible for product transfers and for transition management of local manufacturing plants moving from national to international product supply. This was followed by responsibilities as plant manager at several locations in France and as Senior Vice President of Global Quality Management for 30 plants in the fields of human drugs, biopharmaceuticals, and animal health. Dr. Zimmer is rated a Qualified Person under the German Medicines Act (AMG) and was chief GMP auditor for Boehringer Ingelheim.

He has established an extensive network in the pharmaceutical industry and, as Vice President of European Operations, is manager for the International Society for Pharmaceutical Engineering (ISPE). amp biosimilars AG will benefit from the new Chairman of the Supervisory Board. Dr. Zimmer will bring in his experience and his network, focusing in particular on international production, quality assurance, and supply chain.